Filtros de búsqueda

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

article

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

artículo científico publicado en 2015

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

artículo científico publicado en 2015

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

artículo científico publicado en 2015

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

artículo científico publicado en 2020

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

artículo científico publicado en 2017

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

scientific article published on 23 December 2020

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

artículo científico publicado en 2016

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

artículo científico publicado en 2015

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

artículo científico publicado en 2014

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

scientific article published on 11 May 2020

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

artículo científico publicado en 2015

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy

scientific article published on 28 May 2020

Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis ⬇️

artículo científico publicado el 15 de diciembre de 2010

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma

artículo científico publicado en 2013

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

artículo científico publicado en 2016

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma

artículo científico publicado en 2000

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

artículo científico publicado en 2017

Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma

scientific article published on 14 October 2008

Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis

article

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

artículo científico publicado en 2016

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

artículo científico publicado en 2018

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

artículo científico publicado en 2016

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.

artículo científico publicado en 2018

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

artículo científico publicado en 2015

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

artículo científico publicado en 2013

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

artículo científico publicado en 2018

Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab

artículo científico publicado en 2014

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

artículo científico publicado en 2018

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

artículo científico publicado en 2015

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

scientific article published on 11 January 2019

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

scientific article published on 30 August 2016

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

scientific article published on 06 June 2019

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

artículo científico publicado en 2020

Author Correction: From genes to drugs: targeted strategies for melanoma

artículo científico publicado en 2020

Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

artículo científico publicado en 2019

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

artículo científico publicado en 2013

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Bevacizumab plus ipilimumab in patients with metastatic melanoma

artículo científico publicado en 2014

Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation.

artículo científico publicado en 2016

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

artículo científico publicado en 2015

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

artículo científico publicado en 2003

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

scientific article published on 01 April 2020

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

artículo científico publicado en 2015

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

artículo científico publicado en 2008

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

artículo científico publicado en 2015

Cancer immunotherapy trials: leading a paradigm shift in drug development

artículo científico publicado en 2016

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.

artículo científico publicado en 2018

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

artículo científico publicado en 2016

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

artículo científico publicado en 2013

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

artículo científico

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma

artículo científico publicado en 2017

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

artículo científico publicado en 2013

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

artículo científico publicado en 2015

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

artículo científico publicado en 2018

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma

artículo científico publicado en 2014

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

artículo científico publicado en 2016

Combination immunotherapy: a road map.

artículo científico publicado en 2017

Combinatorial cancer immunotherapy

artículo científico publicado en 2006

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

artículo científico publicado en 2019

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

scientific article published on 01 August 2018

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article published on 01 September 2015

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

artículo científico publicado en 2016

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

scholarly article by Girish S Naik et al published 29 March 2019 in Journal for Immunotherapy of Cancer

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

artículo científico publicado en 2017

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

scientific article published on 08 September 2020

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

artículo científico publicado en 2020

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

artículo científico publicado en 2016

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

artículo científico

Cytotoxic T-lymphocyte-associated antigen-4.

artículo científico publicado en 2011

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

artículo científico publicado en 2016

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

scientific article published on 14 November 2019

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

artículo científico publicado en 2013

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

artículo científico publicado en 2013

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.

artículo científico publicado en 2017

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

artículo científico publicado en 2015

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

artículo científico publicado en 2018

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

artículo científico publicado en 2008

Drug-Related Pneumonitis in the Era of Precision Cancer Therapy

scientific article published on 26 May 2017

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

artículo científico publicado en 2014

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients

artículo científico publicado en 2016

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

artículo científico

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

artículo científico publicado en 2016

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

artículo científico publicado en 2017

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

artículo científico publicado en 2017

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

article

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.

artículo científico publicado en 2018

Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

article

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines

scientific article published on April 2008

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

artículo científico publicado en 2017

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

article

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells

artículo científico publicado en 2011

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

artículo científico publicado en 2017

Expression of T-cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

artículo científico publicado en 2020

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade

scientific article published on 09 September 2020

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

scientific article published on 25 July 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

artículo científico publicado en 2019

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

artículo científico publicado en 2019

From genes to drugs: targeted strategies for melanoma

artículo científico publicado en 2012

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity

artículo científico publicado en 2016

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva

artículo científico publicado en 2016

Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.

artículo científico publicado en 2015

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

artículo científico publicado en 2020

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

artículo científico publicado en 2018

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

artículo científico publicado en 2018

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

artículo científico publicado en 2015

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

artículo científico publicado en 2009

Health-related quality of life results from the phase III CheckMate 067 study.

artículo científico publicado en 2017

Hepatotoxicity with combination of vemurafenib and ipilimumab

artículo científico publicado en 2013

High-throughput oncogene mutation profiling in human cancer

article

Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma

artículo científico publicado en 2002

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX

artículo científico publicado en 2002

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

scientific article published on 20 November 2018

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

artículo científico publicado en 2013

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

artículo científico publicado en 2008

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes

artículo científico publicado en 2016

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

artículo científico publicado en 2018

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions

artículo científico publicado en 2017

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

artículo científico publicado en 2016

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade

scientific article published on 18 July 2019

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma

artículo científico publicado en 2011

Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma

artículo científico publicado en 2014

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.

artículo científico publicado en 2005

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI).

artículo científico publicado en 2015

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

artículo científico publicado en 2008

Immunologic profiling of adenoid cystic carcinoma (acc).

artículo científico publicado en 2015

Immunoprofiling of T cell responses in melanoma patients undergoing CPI therapy.

artículo científico publicado en 2015

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.

artículo científico publicado en 2017

Improved Endpoints for Cancer Immunotherapy Trials ⬇️

artículo científico publicado el 8 de septiembre de 2010

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

scientific article published on 12 July 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

artículo científico publicado en 2010

Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade

artículo científico publicado en 2020

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis

artículo científico publicado en 2016

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

artículo científico publicado en 2015

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy

article

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

artículo científico publicado en 2020

Integrated molecular drivers coordinate biological and clinical states in melanoma

artículo científico publicado en 2020

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1.

artículo científico publicado en 2013

Ipilimumab and its toxicities: a multidisciplinary approach

artículo científico publicado en 2013

Ipilimumab for patients with advanced mucosal melanoma

artículo científico publicado en 2013

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

artículo científico publicado en 2012

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

artículo científico publicado en 2014

KIT gene mutations and copy number in melanoma subtypes

artículo científico publicado en 2008

Landscape of tumor-infiltrating T cell repertoire of human cancers

artículo científico publicado en 2016

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell

scientific article published on 01 March 2007

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

artículo científico publicado en 2015

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

artículo científico publicado en 2020

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2018

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

artículo científico publicado en 2018

MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients

artículo científico publicado el 17 de marzo de 2003

Major response to imatinib mesylate in KIT-mutated melanoma.

artículo científico publicado en 2008

Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors

scientific article published on 22 April 2020

Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

scientific article published on 06 September 2018

Melanoma

artículo científico publicado en 2012

Melanoma

artículo científico publicado en 2009

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.

artículo científico publicado en 2009

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

artículo científico publicado en 2016

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

artículo científico publicado en 2003

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute

artículo científico publicado en 2005

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

artículo científico publicado en 2016

Melanoma, version 2.2013: featured updates to the NCCN guidelines

artículo científico publicado en 2013

Melanoma, version 4.2014.

artículo científico publicado en 2014

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

artículo científico publicado en 2014

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

scientific article published on 25 September 2019

Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.

artículo científico publicado en 2013

Modeling genomic diversity and tumor dependency in malignant melanoma

artículo científico publicado en 2008

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

artículo científico publicado en 2020

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

artículo científico publicado en 2012

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

artículo científico publicado en 2017

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy

artículo científico publicado en 2017

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes

artículo científico publicado en 2016

Mutation-driven drug development in melanoma

artículo científico publicado en 2010

Network for biomarker immunoprofiling for cancer immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

artículo científico publicado en 2021

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

artículo científico publicado en 2017

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

artículo científico publicado en 2015

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

artículo científico publicado en 2017

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

artículo científico publicado en 2015

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service

artículo científico publicado en 2020

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

artículo científico publicado en 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

artículo científico publicado en 2017

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

artículo científico publicado en 2014

Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis

artículo científico publicado en 2020

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

artículo científico publicado en 2014

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

artículo científico publicado en 2016

PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.

artículo científico publicado en 2016

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

artículo científico publicado en 2015

PD-L1 expression in nonclear-cell renal cell carcinoma

artículo científico publicado en 2014

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

artículo científico publicado en 2013

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

artículo científico publicado en 2014

Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study

artículo científico publicado en 2018

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

artículo científico publicado en 2015

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

artículo científico publicado en 2006

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

artículo científico publicado en 2019

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Phase II study of paclitaxel and carboplatin for malignant melanoma

artículo científico publicado en 2002

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

artículo científico publicado en 2016

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

artículo científico publicado en 2019

Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma

artículo científico publicado en 2012

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features

scholarly article by Jonathan D Schoenfeld et al published 24 April 2019 in Journal for Immunotherapy of Cancer

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

artículo científico publicado en 2017

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

artículo científico publicado en 2015

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

artículo científico publicado en 2014

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

artículo científico publicado en 2014

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

artículo científico publicado en 2015

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

artículo científico publicado en 2016

Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways

artículo científico publicado en 2012

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

scientific article published on 01 August 2019

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

artículo científico publicado en 2016

RECIST 1.1-Update and clarification: From the RECIST committee.

artículo científico publicado en 2016

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation

artículo científico publicado en 2017

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2015

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

artículo científico publicado en 2015

Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy

scientific article published on August 2011

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

artículo científico publicado en 2016

Reply to M. Nishino

artículo científico publicado en 2016

Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies

scientific article published on 01 January 2019

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST

scientific article published on 18 June 2020

Response assessment criteria for brain metastases: proposal from the RANO group.

artículo científico publicado en 2015

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

artículo científico publicado en 2014

Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases

artículo científico publicado en 2020

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

artículo científico publicado en 2014

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

artículo científico publicado en 2017

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

scientific article published on 01 December 2018

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

scientific article published on 19 December 2013

Risk of Bias and Heterogeneity-Reply

artículo científico publicado en 2017

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

artículo científico publicado en 2016

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

artículo científico publicado en 2016

Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study

artículo científico publicado en 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

artículo científico publicado en 2020

Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis

scientific article published on 13 May 2020

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

artículo científico publicado en 2019

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

artículo científico publicado en 2012

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

artículo científico publicado en 2018

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

artículo científico publicado en 2015

Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma

scientific article published on 01 September 2020

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

scientific article published on 18 February 2019

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer

artículo científico publicado en 2014

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

artículo científico publicado en 2015

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

scientific article published on 16 June 2016

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

artículo científico publicado en 2016

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

artículo científico publicado en 2015

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors

scientific article published on 15 September 2018

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

artículo científico publicado en 2013

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

artículo científico publicado en 2012

The impact of high-dose glucocorticoids on the outcome of immune checkpoint inhibitor-related thyroid disorders

scientific article published on 14 May 2019

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma

artículo científico publicado en 2012

The role of whole brain radiation therapy in the management of melanoma brain metastases

artículo científico publicado en 2014

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

artículo científico publicado en 2006

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

artículo científico publicado en 2017

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

scientific article published on 09 September 2019

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.

artículo científico publicado en 2017

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

artículo científico publicado en 2017

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

artículo científico publicado en 2016

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

artículo científico publicado en 2016

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

artículo científico publicado en 2003

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma

artículo científico publicado en 2011

Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma.

scientific article published on 28 December 2016

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis

scientific article published on 22 June 2020

When progressive disease does not mean treatment failure: reconsidering the criteria for progression

artículo científico publicado en 2012

c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential

artículo científico publicado en 2012

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

artículo científico publicado en 2017

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

scientific article published on 22 January 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda